Clark Estates Inc’s Haemonetics HAE Stock Holding History

Clark Estates Inc’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-46,000	Closed	-$2.24M	–	103
2025 Q3	$2.24M	Buy	+46,000	New	+$2.85M	0.51%	47

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clark Estates Inc's HAE Position: Q4 2025 in Review

Clark Estates Inc sold out of Haemonetics (HAE) in Q4 2025, closing a stake of 46,000 shares — an estimated $2.24M sold.

Clark Estates Inc first reported a position in HAE in Q3 2025 and held it in 1 quarter. The position peaked at $2.24M in Q3 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q4 2025.

Clark Estates Inc reported no remaining Haemonetics position as of Q4 2025 after selling out during the quarter.
Clark Estates Inc sold 46,000 Haemonetics shares in Q4 2025, an estimated $2.24M.
Clark Estates Inc first reported a position in Haemonetics in Q3 2025 and held it in 1 quarter.
Clark Estates Inc's Haemonetics position peaked at $2.24M in Q3 2025.
329 funds tracked by Wall St. Rank held Haemonetics as of Q4 2025.

Based on Clark Estates Inc's 13F filing for Q4 2025, filed 12 Feb 2026.